Forxiga, a once-daily oral agent, provides physicians with a new option to improve glycaemic control as monotherapy in metformin-intolerant patients or combination therapy Reduction of weight and ...
AstraZeneca today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved FORXIGA® (dapagliflozin in 5 and 10 mg tablets), a sodium-glucose cotransporter 2 (SGLT2) inhibitor ...
AstraZeneca and Bristol-Myers Squibb Company today announced that the European Commission has approved FORXIGA™ (dapagliflozin) tablets for the treatment of type 2 diabetes in the European Union (EU).
The decision comes from positive cardiovascular outcomes and renal data from the Phase III DECLARE-TIMI 58 trial. The European Commission has approved an update to the marketing authorisation for ...
AstraZeneca’s diabetes drug Forxiga (dapagliflozin) has been approved in the EU in patients with type 1 disease. Forxiga has been approved as an adjunct to insulin in patients with a BMI greater than ...
AstraZeneca plc. AZN announced that the Japanese regulatory authority has granted marketing approval to its SGLT2 inhibitor Forxiga for a new indication — as an oral adjunct treatment to insulin in ...
The drug is the first oral medicine approved in Europe as an adjunct to insulin for adults with type I diabetes. AstraZeneca’s Forxiga (dapagliflozin), has been approved by the European Commission (EC ...
Forxiga is the first oral medicine approved in Europeas an adjunct to insulin for adults with type-1 diabetes and thefirst AstraZeneca medicine ever approved for type-1 diabetes The European ...
AstraZeneca plcAZN announced that the European Commission (EC) has approved a label expansion of its diabetes drug, Forxiga (dapagliflozin). Forxiga has been approved for the treatment of type-1 ...
AstraZeneca today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved FORXIGA® (dapagliflozin in 5 and 10 mg tablets), a sodium-glucose cotransporter 2 (SGLT2) inhibitor ...
Forxiga tablets are indicated as a once-daily oral medication to improve glycaemic control in adult patients with type 2 diabetes. Forxiga is intended to be used as an adjunct to diet and exercise in ...
The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Forxiga (dapagliflozin) as an oral adjunct treatment to insulin for adults with type-1 diabetes (T1D). The approval is based on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback